401,800 Shares in Fresenius Medical Care AG & Co. KGaA $FMS Purchased by Hennessy Advisors Inc.

Hennessy Advisors Inc. purchased a new position in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 401,800 shares of the company’s stock, valued at approximately $11,479,000. Hennessy Advisors Inc. owned about 0.07% of Fresenius Medical Care AG & Co. KGaA as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wayfinding Financial LLC purchased a new position in Fresenius Medical Care AG & Co. KGaA during the first quarter worth about $25,000. Spire Wealth Management purchased a new position in Fresenius Medical Care AG & Co. KGaA during the first quarter worth about $27,000. Brooklyn Investment Group boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 424.5% during the first quarter. Brooklyn Investment Group now owns 1,285 shares of the company’s stock worth $32,000 after purchasing an additional 1,040 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 33.3% during the first quarter. Russell Investments Group Ltd. now owns 4,200 shares of the company’s stock worth $105,000 after purchasing an additional 1,049 shares during the last quarter. Finally, TD Private Client Wealth LLC boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 6,380.3% during the second quarter. TD Private Client Wealth LLC now owns 4,925 shares of the company’s stock worth $141,000 after purchasing an additional 4,849 shares during the last quarter. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

Fresenius Medical Care AG & Co. KGaA Trading Up 0.5%

NYSE FMS opened at $26.76 on Friday. The company’s 50 day moving average is $25.20 and its 200-day moving average is $26.13. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $18.94 and a 12-month high of $30.46. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.44 and a quick ratio of 1.08.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.02. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.39% and a return on equity of 6.75%. The company had revenue of $5.54 billion for the quarter, compared to analyst estimates of $5 billion. Equities research analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current year.

Wall Street Analyst Weigh In

FMS has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Saturday, September 27th. UBS Group reiterated a “sell” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, September 2nd. Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 12th. Zacks Research cut shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 18th. Finally, Wall Street Zen cut shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 5th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA presently has a consensus rating of “Reduce” and a consensus price target of $27.80.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.